Pliant Therapeutics Poised for Growth: A Strong Buy on Promising Drug Pipeline and Strategic Leadership

Analyst Joseph Stringer of Needham maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price target of $38.00.

TipRanksApr 10 18:45

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage

GlobeNewswireMar 27 22:23

MASI, PLRX and CGC Are Among After Hour Movers

Seeking AlphaMar 23 04:59

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)

TipRanksMar 13 19:11

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)

TipRanksMar 13 00:50

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announce

BenzingaMar 12 19:35